GlobeNewswire by notified

Huhtamaki partners with RiverRecycle and VTT to develop technology to tackle floating river waste. New technology river waste collector now operational on the Mithi River in Mumbai, India

Share

HUHTAMÄKI OYJ PRESS RELEASE 27.8.2021 AT 07:00 EET

Huhtamaki partners with RiverRecycle and VTT to develop technology to tackle floating river waste. New technology river waste collector now operational on the Mithi River in Mumbai, India

Finding new ways to address our environmental challenges is reliant on our ability to foster innovation to find ways of driving systemic change. To support such innovation and progress towards circularity, Huhtamaki, a key global provider of sustainable packaging solutions for consumers around the world, donated €600,000 to fund the development and piloting of a river waste collector, invented by the Finnish cleantech start-up RiverRecycle. The collector is an integral part of RiverRecycle’s solution to solve marine waste, one of the biggest global challenges of today. With Huhtamaki’s support, a prototype waste collector was built and tested in Finland. This was then transported to and assembled in Mumbai, where it is now operational and where it will be collecting waste from the Mithi River for the next 12 months.

“We believe in protecting food, people and the planet. We also believe that cooperation across the value chain with key stakeholders is needed to address global sustainability challenges, for example such as in this case marine plastics. If we want to drive systemic change, we not only need to support the development and commercialization of innovation that can help stop waste from getting into the oceans, but we also need the monetization of waste and incentivization of local communities to improve their waste management practices,” says Thomasine Kamerling, Executive Vice President Sustainability and Communications at Huhtamaki.

“When operating in a circular economy, cooperation among different players is fundamental to sustainability. Huhtamaki funding enabled us to complete two of the three parts of our journey of transforming plastic waste into a resource, with the positive engagement of affected communities. Huhtamaki’s commitment is an example of how collaboration helps solve global problems such as plastic waste pollution," says Anssi Mikola, CEO and Founder of RiverRecycle.

The Mithi River project is run by a global partnership between UNTIL (now known as UN Global Pulse), VTT Technical Research Centre of Finland Ltd, RiverRecycle and Earth5R, an India-based citizen-led environmental movement. In addition to building, setting up and operating the river cleaner for a year, Huhtamaki’s donation has been used to organize local hands-on workshops on effective waste management and recycling with a view to drive systemic change. The project also provides input to VTT Technical Research Centre of Finland on the floating waste and its seasonal variations that can be used to optimize clean-up operations and recycling processes for the future.

“The Huhtamaki funding enables the adaption of optical sensors and drones in the detection of floating plastic objects and differentiation of plastics from organic material. VTT’s contribution also includes pyrolysis test runs and assessing chemical recycling of the recovered plastic waste fractions. At a broader level we aim to enhance circular economy solutions for the global challenge of plastic waste pollution. In addition to the technology involvement, we also appreciate the collaboration between local partners and communities as an essential part of the successful project implementation,” says Jukka Sassi, Senior Scientist, VTT Technical Research Centre of Finland Ltd.

Huhtamaki’s ambition is to have 100% of its products designed to be recyclable, reusable or compostable by 2030. In India, where Huhtamaki has 16 units and manufactures mainly high-quality flexible packaging that protect for example food, pharmaceuticals and personal and home care products, the Company has already several recyclable flexible packaging structures in the market under its Huhtamaki blueloop concept. In addition to the Mithi River project, Huhtamaki is contributing to the building of necessary recycling infrastructure by setting up a pilot recycling plant for flexible packaging in India which should be operational by the end of 2021.

‘’We are excited to be a part of this global partnership and the development of the technology enabling us to clean Mithi, the only river that flows through the heart of Mumbai. This project promotes sustainability with a holistic approach by collecting plastic waste, while also empowering local communities to gain knowledge and employment,’’ notes Sudip Mall, Managing Director, Flexible Packaging India at Huhtamaki.

The Mithi River project is one of three initiatives that Huhtamaki funded as part of its 100-year anniversary to address global sustainability challenges and build and learn from circular economy initiatives globally.

For further information, please contact:
Katariina Hietaranta, Head of Media Relations, tel. +358 10 686 7863

For more information and materials on the Mithi River project, please visit: https://www.riverrecycle.com/india-mithi-river-cleanup/

HUHTAMÄKI OYJ
Global Communications

About Huhtamaki
Huhtamaki is a key global provider of sustainable packaging solutions for consumers around the world, enabling wellbeing and convenience. Our innovative products protect on-the-go and on-the-shelf food and beverages, ensuring hygiene and safety, and help prevent food waste. We embed sustainability in everything we do. We are committed to achieving carbon neutral production and designing all our products to be recyclable, compostable or reusable by 2030.

We are a participant in the UN Global Compact and as of 2020, we received an MSCI ESG Rating of A, on a scale of AAA ─ CCC. To play our part in managing climate change, we have committed to set science-based targets through the Science Based Targets initiative. Huhtamaki has been awarded the Gold medal by EcoVadis for performance in sustainability.

With 100 years of history and a strong Nordic heritage we operate in 36 countries and 82 sites around the world. Our values Care Dare Deliver guide our decisions and help our team of 18,200 employees make a difference where it matters. Our 2020 net sales totaled EUR 3.3 billion. Huhtamaki Group is headquartered in Espoo, Finland and our parent company, Huhtamäki Oyj, is listed on Nasdaq Helsinki Ltd. Find out more about how we are protecting food, people and the planet on www.huhtamaki.com.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin

Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

HiddenA line styled icon from Orion Icon Library.Eye